F. Hoffmann-La Roche sees highest patent filings and grants during August in Q3 2023
F. Hoffmann-La Roche saw the highest growth of 110% in patent filings and 145% in grants in August in Q3 2023. Compared to Q2 2023, Q3 2023 saw an increase in patent filings by 79% and grants by 98%. GlobalData's DataBook provides a comprehensive analysis of F. Hoffmann-La Roche's patent filings and grants. Buy the databook here. F. Hoffmann-La Roche has been focused on protecting inventions in United States(US) with 333 publications in Q3 2023The United States(US) Patent Office dominates the patent filings and grants with nearly 19% filings and 23% grants. The United States(US), European Patent Office (E/P), China(CN), and Japan(JP) patent Office are among the top ten patent offices where F. Hoffmann-La Roche is filings its patents. Among the top granted patent authorities, F. Hoffmann-La Roche has 23% of its grants in United States(US), 23% in European Patent Office (E/P), and 11% in China(CN). Amgen could be the strongest competitor for F. Hoffmann-La RocheIn terms of grant share, F. Hoffmann-La Roche stands in one position among its competitors. Amgen and Johnson & Johnson secured the top positions according to recent patent publication data. Patents related to healthtech and rare diseases lead F. Hoffmann-La Roche's portfolioF. Hoffmann-La Roche has the highest number of patents in healthtech followed by, rare diseases and climate change. For healthtech, nearly 20% of patents were filed and 16% of patents were granted in Q3 2023. Healthcare it related patents lead F. Hoffmann-La Roche portfolio followed by image management, and breast cancerF. Hoffmann-La Roche has highest number of patents in healthcare it followed by image management, breast cancer, medical device and drug delivery devices. For healthcare it, nearly 5% of patents were filed and 2% of patents were granted in Q3 2023. For comprehensive analysis of F. Hoffmann-La Roche's filings and grants, buy the databook here.
Access and buy GlobalData’s databook on the latest filings and grants activity for F. Hoffmann-La Roche here.
What's Your Reaction?
